The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemotherapeutic agents in preclinical tumor models

Molecular Cancer Therapeutics

Volumn 14, Issue 4, 2015, Pages 931-940

  Foster, Paul ^a   Yamaguchi, Kyoko ^a   Hsu, Pin P ^a   Qian, Fawn ^a   Du, Xiangnan ^a   Wu, Jianming ^a   Won, Kwang Ai ^a   Yu, Peiwen ^a   Jaeger, Christopher T ^a   Zhang, Wentao ^a   Marlowe, Charles K ^a   Keast, Paul ^a   Abulafia, Wendy ^a   Chen, Jason ^a   Young, Jenny ^a   Plonowski, Artur ^a   Yakes, F Michael ^a   Chu, Felix ^a   Engell, Kelly ^a   Bentzien, Frauke ^a   Lam, Sanh T ^a   Dale, Stephanie ^a   Yturralde, Olivia ^a   Matthews, David J ^a   Lamb, Peter ^a   Laird, A Douglas ^a   more..

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLIN D1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PILARALISIB; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P110DELTA; PROTEIN P120; PROTEIN P120GAMMA; S6 KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; INHIBITION CONSTANT; LOSS OF FUNCTION MUTATION; MALE; MELANOMA; MICHAELIS CONSTANT; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REPEATED DRUG DOSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937515889     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0833     Document Type: Article

References (28)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
2. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56.
3. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96.
4. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008;105: 8292-7.
5. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
6. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, et al. RAS andRHOfamilies of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013;153:1050-63.
7. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7:209-19.
8. García-Echeverría C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010;20:4308-12.
9. COSMIC database [Internet]. Hinxton: Wellcome Trust Sanger Institute (UK). PIK3CA gene search. [cited 2014 Dec 12]. Available from: http://cancer.sanger.ac.uk/cosmic/gene/overview?search=&ln=PIK3CA.
10. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
11. Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, et al. PI3K isoformdependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 2014;111:6395-400.
12. BurrisHA 3rd.Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 71:829-42.
13. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 2014;13:1021-31.
14. Yu P, Laird AD,DuX,WuJ,WonKA, Yamaguchi K, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther 2014;13:1078-91.
15. Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, et al. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. Bioorg Med Chem Lett 2012;22:2283-6.
16. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10: 2298-308.
17. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56.
18. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
19. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51.
20. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-55.
21. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
22. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17:3272-81.
23. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
24. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014;20:233-45.
25. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CAmutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73:276-84.
26. Traynor AM, Kurzrock R, Bailey HH, Attia S, Scheffold C, van Leeuwen B, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors 2010 ASCO Annual Meeting. J Clin Oncol 2010;28:15s.
27. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012;109:2718-23.
28. Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 2013;73:1190-200.